Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. (NASDAQ: DYN) is a clinical-stage biotechnology leader advancing targeted therapies for genetically driven neuromuscular diseases through its proprietary FORCE™ platform. This page provides investors, researchers, and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's progress.
Access real-time announcements including clinical trial results, research collaborations, and regulatory filings alongside analysis of pipeline advancements for conditions like myotonic dystrophy and Duchenne muscular dystrophy. Our curated news collection ensures you stay informed about therapeutic innovations leveraging Dyne's novel approach to muscle-targeted oligonucleotide delivery.
Bookmark this page for direct access to earnings reports, scientific presentations, and partnership announcements that demonstrate Dyne's commitment to addressing high unmet needs in neuromuscular care. Regularly updated to reflect the latest developments in their mission to transform treatment paradigms.
Dyne Therapeutics reported positive clinical data from its Phase 1/2 ACHIEVE trial of DYNE-101 for myotonic dystrophy type 1 (DM1) and its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy (DMD). DYNE-101 showed a 27% mean splicing correction and improvements in muscle strength and timed function tests in DM1 patients. DYNE-251 demonstrated a 7.6% mean muscle-adjusted dystrophin expression in DMD patients, significantly surpassing the standard of care levels. Both treatments exhibited favorable safety profiles, encouraging trends in functional improvements, and no serious adverse events. Dyne aims to seek expedited approvals with updates on registration pathways by the end of 2024.
Dyne Therapeutics (Nasdaq: DYN) will host a virtual investor event on May 20, 2024, at 8:00 a.m. ET to discuss new clinical data from its Phase 1/2 ACHIEVE and DELIVER trials. The ACHIEVE trial focuses on DYNE-101 for myotonic dystrophy type 1 (DM1) and has enrolled 56 patients. Efficacy data from various cohorts will be presented. The DELIVER trial evaluates DYNE-251 for Duchenne muscular dystrophy (DMD) and has enrolled 48 patients. Safety, tolerability, and efficacy data, including dystrophin expression, will be discussed.
Both trials aim to provide comprehensive pharmacokinetic and pharmacodynamic data. The event will be webcast live and available for replay for 90 days.
Dyne Therapeutics, Inc. (Nasdaq: DYN) reported financial results for Q1 2024 and recent business highlights. The company focuses on innovative therapeutics for muscle diseases, anticipating additional clinical data from the ACHIEVE and DELIVER trials in the second half of 2024. With a strong cash position, Dyne aims to initiate registrational cohorts by year-end.
FAQ
What is the current stock price of Dyne Therapeutics (DYN)?
What is the market cap of Dyne Therapeutics (DYN)?
